Novel Therapeutic Applications of RhoA Inhibitors and mTOR Inhibitors

The inventive concept expands the therapeutic potential of RhoA inhibitors and mTOR inhibitors beyond Lowe Syndrome to address unmet needs in chronic skin conditions, muscle atrophy, neurodegenerative diseases, wound healing, and respiratory diseases.

The original patent disclosed the use of RhoA inhibitors, statins, and mTOR inhibitors for the treatment of Lowe Syndrome. However, the full therapeutic potential of these compounds remains untapped. The inventive concept addresses the limitations of the original patent by exploring new applications and use cases for these compounds, providing novel solutions for underserved diseases and conditions.

The inventive concept comprises four primary embodiments: (1) a system for treating chronic skin conditions using topical compositions of RhoA inhibitors and mTOR inhibitors, (2) a method for reducing muscle atrophy in astronauts during space travel via pharmaceutical compositions of RhoA inhibitors and statins, (3) a composition for treating neurodegenerative diseases by combining RhoA inhibitors, mTOR inhibitors, and neuroprotective agents, and (4) a system for enhancing wound healing using biodegradable matrices containing RhoA inhibitors and mTOR inhibitors. These embodiments leverage the synergistic effects of RhoA inhibitors and mTOR inhibitors to address specific disease mechanisms and pathways.

The inventive concept introduces new and non-obvious applications of RhoA inhibitors and mTOR inhibitors, departing from the original patent's focus on Lowe Syndrome. The combination of these compounds with other therapeutic agents and their application to diverse disease areas constitutes a novel and inventive step.

Alternative embodiments of the inventive concept could include the use of different RhoA inhibitors or mTOR inhibitors, varying the dosage and administration routes, or combining these compounds with other therapeutic agents to address specific disease mechanisms. Additionally, the inventive concept could be adapted for use in veterinary medicine or in conjunction with other treatment modalities, such as gene therapy or stem cell therapy.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in dermatology, neurology, respiratory medicine, and space medicine. The target market includes patients suffering from chronic skin conditions, muscle atrophy, neurodegenerative diseases, and respiratory diseases, as well as astronauts and individuals at risk of developing these conditions.